Metabolic depletion of sphingolipids inhibits agonist-induced endocytosis of the serotonin
G protein-coupled receptor
endocytosis
fumonisin B1
serotonin1A receptor
sphingolipids
sphingomyelin
Journal
Traffic (Copenhagen, Denmark)
ISSN: 1600-0854
Titre abrégé: Traffic
Pays: England
ID NLM: 100939340
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
11
10
2022
received:
11
05
2022
accepted:
18
10
2022
pubmed:
20
12
2022
medline:
26
1
2023
entrez:
19
12
2022
Statut:
ppublish
Résumé
G protein-coupled receptors (GPCRs) are vital cellular signaling machinery and currently represent ~40% drug targets. Endocytosis of GPCRs is an important process that allows stringent spatiotemporal control over receptor population on the cell surface. Although the role of proteins in GPCR endocytosis is well addressed, the contribution of membrane lipids in this process is rather unexplored. Sphingolipids are essential functional lipids in higher eukaryotes and are implicated in several neurological functions. To understand the role of sphingolipids in GPCR endocytosis, we subjected cells expressing human serotonin
Substances chimiques
Receptors, G-Protein-Coupled
0
Serotonin
333DO1RDJY
Sphingolipids
0
HTR1A protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-107Subventions
Organisme : Council of Scientific and Industrial Research, India
Organisme : CSIR FBR
ID : MLP 0146
Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3(9):639-650.
Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459(7245):356-363.
Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature. 2013;494(7436):185-194.
Chattopadhyay A. GPCRs: lipid dependent membrane receptors that act as drug targets. Adv Biol. 2014;2014:143023.
Jacobson KA. New paradigms in GPCR drug discovery. Biochem Pharmacol. 2015;98(4):541-555.
Insel PA, Sriram K, Gorr MW, et al. GPCRomics: an approach to discover GPCR drug targets. Trends Pharmacol Sci. 2019;40(6):378-387.
Chan HCS, Li Y, Dahoun T, Vogel H, Yuan S. New binding sites, new opportunities for GPCR drug discovery. Trends Biochem Sci. 2019;44(4):312-330.
Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev. 2001;53(1):1-24.
Hanyaloglu AC, von Zastrow M. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol. 2008;48:537-568.
Magalhaes AC, Dunn H, Ferguson SS. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol. 2012;165(6):1717-1736.
Irannejad R, Tsvetanova NG, Lobingier BT, von Zastrow M. Effects of endocytosis on receptor-mediated signaling. Curr Opin Cell Biol. 2015;35:137-143.
Thomsen ARB, Jensen DD, Hicks GA, Bunnett NW. Therapeutic targeting of endosomal G-protein-coupled receptors. Trends Pharmacol Sci. 2018;39(10):879-891.
Weinberg ZY, Crilly SE, Puthenveedu MA. Spatial encoding of GPCR signaling in the nervous system. Curr Opin Cell Biol. 2019;57:83-89.
Crilly SE, Puthenveedu MA. Compartmentalized GPCR signaling from intracellular membranes. J Membr Biol. 2021;254(3):259-271.
Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev. 1997;77(3):759-803.
Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857-902.
Kaksonen M, Roux A. Mechanisms of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2018;19(5):313-326.
Pal S, Chattopadhyay A. Extramembranous regions in G protein-coupled receptors: Cinderella in receptor biology? J Membr Biol. 2019;252(4-5):483-497.
Holthuis JC, Pomorski T, Raggers RJ, Sprong H, Van Meer G. The organizing potential of sphingolipids in intracellular membrane transport. Physiol Rev. 2001;81(4):1689-1723.
van Meer G, de Kroon AI. Lipid map of the mammalian cell. J Cell Sci. 2011;124:5-8.
Hanada K. Sphingolipids in infectious diseases. Jpn J Infect Dis. 2005;58(3):131-148.
Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19(3):175-191.
Lange Y, Swaisgood MH, Ramos BV, Steck TL. Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. J Biol Chem. 1989;264(7):3786-3793.
Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. Nat Rev Mol Cell Biol. 2018;19(5):281-296.
Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387(6633):569-572.
Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1(1):31-39.
Simons K, van Meer G. Lipid sorting in epithelial cells. Biochemistry. 1988;27(17):6197-6202.
Klemm RW, Ejsing CS, Surma MA, et al. Segregation of sphingolipids and sterols during formation of secretory vesicles at the trans-Golgi network. J Cell Biol. 2009;185(4):601-612.
Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6(2):112-126.
Jafurulla M, Chattopadhyay A. Sphingolipids in the function of G protein-coupled receptors. Eur J Pharmacol. 2015;763:241-246.
Pucadyil TJ, Kalipatnapu S, Chattopadhyay A. The serotonin1A receptor: a representative member of the serotonin receptor family. Cell Mol Neurobiol. 2005;25(3-4):553-580.
Kalipatnapu S, Chattopadhyay A. Membrane organization and function of the serotonin1A receptor. Cell Mol Neurobiol. 2007;27(8):1097-1116.
Müller CP, Carey RJ, Huston JP, De Souza Silva MA. Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Prog Neurobiol. 2007;81(3):133-178.
Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry. 2009;66(7):627-635.
Fiorino F, Severino B, Magli E, et al. 5-HT1A receptor: an old target as a new attractive tool in drug discovery from central nervous system to cancer. J Med Chem. 2014;57(11):4407-4426.
Kaufman J, DeLorenzo C, Choudhury S, Parsey RV. The 5-HT1A receptor in major depressive disorder. Eur Neuropsychopharmacol. 2016;26(3):397-410.
Sarkar P, Kumar GA, Pal S, Chattopadhyay A. Biophysics of serotonin and the serotonin1A receptor: fluorescence and dynamics. In: Pilowsky P, ed. Serotonin: the Mediator that Spans Evolution. Elsevier; 2018:3-22.
Sarkar P, Mozumder P, Bej A, Mukherjee S, Sengupta J, Chattopadhyay A. Structure, dynamics and lipid interactions of serotonin receptors: excitements and challenges. Biophys Rev. 2021;13:101-122.
Nutt DJ, Forshall S, Bell C, et al. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol. 1999;9:S81-S86.
Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psych. 2003;27(1):85-102.
Riad M, Zimmer L, Rbah L, Watkins KC, Hamon M, Descarries L. Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rat. J Neurosci. 2004;24(23):5420-5426.
Descarries L, Riad M. Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos Trans R Soc Lond B Biol Sci. 2012;367(1601):2416-2425.
Kumar GA, Sarkar P, Jafurulla M, et al. Exploring endocytosis and intracellular trafficking of the human serotonin1A receptor. Biochemistry. 2019;58(22):2628-2641.
Kumar GA, Chattopadhyay A. Statin-induced chronic cholesterol depletion switches GPCR endocytosis and trafficking: insights from the serotonin1A receptor. ACS Chem Nerosci. 2020;11(3):453-465.
Kumar GA, Chattopadhyay A. Membrane cholesterol regulates endocytosis and trafficking of the serotonin1A receptor: insights from acute cholesterol depletion. Biochim Biophys Acta. 2021;1866(4):158882.
Sharma A, Kumar GA, Chattopadhyay A. Late endosomal/lysosomal accumulation of a neurotransmitter receptor in a cellular model of Smith-Lemli-Opitz syndrome. Traffic. 2021;22(10):332-344.
Kumar GA, Chattopadhyay A. Cholesterol-dependent endocytosis of GPCRs: implications in pathophysiology and therapeutics. Biophys Rev. 2021;13(6):1007-1017.
Paila YD, Ganguly S, Chattopadhyay A. Metabolic depletion of sphingolipids impairs ligand binding and signaling of human serotonin1A receptors. Biochemistry. 2010;49(11):2389-2397.
Ganguly S, Paila YD, Chattopadhyay A. Metabolic depletion of sphingolipids enhances the mobility of the human serotonin1A receptor. Biochem Biophys Res Commun. 2011;411(1):180-184.
Singh P, Paila YD, Chattopadhyay A. Role of glycosphingolipids in the function of human serotonin1A receptors. J Neurochem. 2012;123(5):716-724.
Jafurulla M, Pucadyil TJ, Chattopadhyay A. Effect of sphingomyelinase treatment on ligand binding activity of human serotonin1A receptors. Biochim Biophys Acta. 2008;1778(10):2022-2025.
Prasanna X, Jafurulla M, Sengupta D, Chattopadhyay A. The ganglioside GM1 interacts with the serotonin1A receptor via the sphingolipid binding domain. Biochim Biophys Acta. 2016;1858(11):2818-2826.
Jafurulla M, Bandari S, Pucadyil TJ, Chattopadhyay A. Sphingolipids modulate the function of human serotonin1A receptors: insights from sphingolipid-deficient cells. Biochim Biophys Acta. 2017;1859(4):598-604.
Kumar A, Sarkar P, Chattopadhyay A. Metabolic depletion of sphingolipids reduces cell surface population of the human serotonin1A receptor due to impaired trafficking. ACS Chem Nerosci. 2021;12(7):1189-1196.
Wang E, Norred WP, Bacon CW, Riley RT, Merrill AH Jr. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J Biol Chem. 1991;266(22):14486-14490.
Voss KA, Riley RT. Fumonisin toxicity and mechanism of action: overview and current perspectives. Food Safety. 2013;1(1):49-69.
Hopkins CR, Trowbridge IS. Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J Cell Biol. 1983;97(2):508-521.
Kolter T, Sandhoff K. Sphingolipid metabolism diseases. Biochim Biophys Acta. 2006;1758(12):2057-2079.
Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1-23.
Monasterio BG, Jiménez-Rojo N, García-Arribas AB, Riezman H, Goñi FM, Alonso A. CHO/LY-B cell growth under limiting sphingolipid supply: correlation between lipid composition and biophysical properties of sphingolipid-restricted cell membranes. FASEB J. 2021;35(6):e21657.
Shrivastava S, Sarkar P, Preira P, Salomé L, Chattopadhyay A. Role of Actin cytoskeleton in dynamics and function of the serotonin1A receptor. Biophys J. 2020;118(4):944-956.
von Kleist L, Stahlschmidt W, Bulut H, et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell. 2011;146(3):471-484.
Zeidan YH, Hannun YA. Translational aspects of sphingolipid metabolism. Trends Mol Med. 2007;13(8):327-336.
Fantini J, Barrantes FJ. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta. 2009;1788(11):2345-2361.
Olsen ASB, Faergeman NJ. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol. 2017;7(5):170069.
Wu G, Lu ZH, Kulkarni N, Ledeen RW. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J Neurosci Res. 2012;90(10):1997-2008.
Di Scala C, Yahi N, Flores A, et al. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides. Biochim Biophys Acta. 2016;1862(2):213-222.
van Echten-Deckert G, Walter J. Sphingolipids: critical players in Alzheimer's disease. Prog Lipid Res. 2012;51(4):378-393.
Crivelli SM, Giovagnoni C, Visseren L, et al. Sphingolipids in Alzheimer's disease, how can we target them? Adv Drug Deliv Rev. 2020;159:214-231.
Fantini J, Chahinian H, Yahi N. Progress toward Alzheimer's disease treatment: leveraging the Achilles' heel of Aβ oligomers? Protein Sci. 2020;29(8):1748-1759.
Tan SK, Hartung H, Sharp T, Temel Y. Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus? Neuropharmacology. 2011;61(3):387-399.
Wirth A, Holst K, Ponimaskin E. How serotonin receptors regulate morphogenic signalling in neurons. Prog Neurobiol. 2017;151:35-56.
Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007;95(1-3):158-168.
Haleem DJ. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia. Behav Pharmacol. 2015;26(1-2):45-58.
Maxfield FR. Role of endosomes and lysosomes in human disease. Cold Spring Harb Perspect Biol. 2014;6(5):a016931.
Platt FM. Sphingolipid lysosomal storage disorders. Nature. 2014;510(7503):68-75.
Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013;5(12):a016949.
Dawaliby R, Trubbia C, Delporte C, et al. Phosphatidylethanolamine is a key regulator of membrane fluidity in eukaryotic cells. J Biol Chem. 2016;291(7):3658-3667.
Mahfoud R, Garmy N, Maresca M, Yahi N, Puigserver A, Fantini J. Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins. J Biol Chem. 2002;277(13):11292-11296.
Contreras FX, Ernst AM, Haberkant P, et al. Molecular recognition of a single sphingolipid species by a protein's transmembrane domain. Nature. 2012;481(7382):525-529.
Slotte JP. Biological functions of sphingomyelins. Prog Lipid Res. 2013;52(4):424-437.
Snook CF, Jones JA, Hannun YA. Sphingolipid-binding proteins. Biochim Biophys Acta. 2006;1761(8):927-946.
Chattopadhyay A, Paila YD, Shrivastava S, Tiwari S, Singh P, Fantini J. Sphingolipid-binding domain in the serotonin1A receptor. Adv Exp Med Biol. 2012;749:279-293.
Shrivastava S, Jafurulla M, Tiwari S, Chattopadhyay A. Identification of sphingolipid-binding motif in G protein-coupled receptors. Adv Exp Med Biol. 2018;1112:141-149.
Sarkar P, Chattopadhyay A. Cholesterol interaction motifs in G protein-coupled receptors: slippery hot spots? Wiley Interdiscip Rev Syst Biol Med. 2020;12(4):e1481.
Bretscher MS, Munro S. Cholesterol and the Golgi apparatus. Science. 1993;261(5126):1280-1281.
Quinn PJ. Structure of sphingomyelin bilayers and complexes with cholesterol forming membrane rafts. Langmuir. 2013;29(30):9447-9456.
Sharpe HJ, Stevens TJ, Munro S. A comprehensive comparison of transmembrane domains reveals organelle-specific properties. Cell. 2010;142(1):158-169.
Brown RE. Sphingolipid organization in biomembranes: what physical studies of model membranes reveal. J Cell Sci. 1998;111:1-9.
Lippincott-Schwartz J, Phair RD. Lipids and cholesterol as regulators of traffic in the endomembrane system. Annu Rev Biophys. 2010;39:559-578.
Trubiani O, Guarnieri S, Orciani M, Salvolini E, Di Primio R. Sphingolipid microdomains mediate CD38 internalization: topography of the endocytosis. Int J Immunopathol Pharmacol. 2004;17(3):293-300.
Pepperl J, Reim G, Lüthi U, Kaech A, Hausmann G, Basler K. Sphingolipid depletion impairs endocytic traffic and inhibits wingless signaling. Mech Dev. 2013;130(9-10):493-505.
Tani M, Kuge O. Involvement of complex sphingolipids and phosphatidylserine in endosomal trafficking in yeast Saccharomyces cerevisiae. Mol Microbiol. 2012;86(5):1262-1280.
Zanolari B, Friant S, Funato K, Sütterlin C, Stevenson BJ, Riezman H. Sphingoid base synthesis requirement for endocytosis in Saccharomyces cerevisiae. EMBO J. 2000;19(12):2824-2833.
Harikumar KG, Puri V, Singh RD, Hanada K, Pagano RE, Miller LJ. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem. 2005;280(3):2176-2185.
Kalipatnapu S, Pucadyil TJ, Harikumar KG, Chattopadhyay A. Ligand binding characteristics of the human serotonin1A receptor heterologously expressed in CHO cells. Biosci Rep. 2004;24(2):101-115.
Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76-85.
Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917.
Dragusin M, Gurgui C, Schwarzmann G, Hoernschemeyer J, van Echten-Deckert G. Metabolism of the unnatural anticancer lipid safingol, L-threo-dihydrosphingosine, in cultured cells. J Lipid Res. 2003;44(9):1772-1779.
Amundson DM, Zhou M. Fluorometric method for the enzymatic determination of cholesterol. J Biochem Biophys Methods. 1999;38(1):43-52.